Publications

De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM et al..  2013.  Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.. PLoS Genet. 9(1):e1003137.

Beguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.

Clozel T, Yang SN, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW et al..  2013.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.. Cancer Discov. 3(9):1002-19.

Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SNing et al..  2012.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.. Cancer Cell. 22(6):812-24.

Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SNing, Figueroa ME, Morin RD, Hirst M, Mendez L, Shaknovich R, Cole PA et al..  2010.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.. J Clin Invest. 120(12):4569-82.

Shaknovich R, Geng H, Johnson NA, Tsikitas L, Cerchietti L, Greally JM, Gascoyne RD, Elemento O, Melnick A.  2010.  DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma.. Blood. 116(20):e81-9.

Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SNing, Ye K, Farinha P, Horsman DE, Gascoyne RD et al..  2009.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.. Blood. 113(22):5536-48.

Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.  2008.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.. Cancer Res. 68(9):3361-9.